{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "ATRECA INC.A SHS DL-,0001", "longName": "Atreca, Inc.", "messageBoardId": "finmb_141813615", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "marketState": "REGULAR", "epsTrailingTwelveMonths": -2.36, "epsForward": -2.75, "epsCurrentYear": -2.93, "priceEpsCurrentYear": -0.29522184, "sharesOutstanding": 32441100, "bookValue": 2.007, "fiftyDayAverage": 1.0745, "fiftyDayAverageChange": -0.20949996, "fiftyDayAverageChangePercent": -0.19497438, "twoHundredDayAverage": 1.403225, "twoHundredDayAverageChange": -0.53822494, "twoHundredDayAverageChangePercent": -0.38356283, "marketCap": 32690772, "forwardPE": -0.31454545, "priceToBook": 0.43099153, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "firstTradeDateMilliseconds": 1561442400000, "priceHint": 4, "regularMarketChangePercent": -14.356434, "regularMarketPrice": 0.865, "regularMarketChange": -0.14499998, "regularMarketTime": 1683875702, "regularMarketDayHigh": 0.865, "regularMarketDayRange": "0.865 - 0.865", "regularMarketDayLow": 0.865, "regularMarketVolume": 2460, "regularMarketPreviousClose": 1.01, "bid": 0.965, "ask": 0.995, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.865, "averageDailyVolume3Month": 41, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.14499998, "fiftyTwoWeekLowChangePercent": 0.20138885, "fiftyTwoWeekRange": "0.72 - 2.66", "fiftyTwoWeekHighChange": -1.7950001, "fiftyTwoWeekHighChangePercent": -0.674812, "fiftyTwoWeekLow": 0.72, "fiftyTwoWeekHigh": 2.66, "earningsTimestamp": 1683749125, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "tradeable": false, "cryptoTradeable": false, "symbol": "0C1.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "835 Industrial Road", "address2": "Suite 400", "city": "South San Francisco", "state": "CA", "zip": "94070", "country": "United States", "phone": "650 595 2595", "fax": "650 453 2410", "website": "https://www.atreca.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.", "fullTimeEmployees": 90, "companyOfficers": [{"maxAge": 1, "name": "Mr. John A. Orwin M.B.A.", "age": 57, "title": "Pres, CEO & Director", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 927033, "fmt": "927.03k", "longFmt": "927,033"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tito A. Serafini Ph.D.", "age": 59, "title": "Founder, Chief Strategy Officer & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 665504, "fmt": "665.5k", "longFmt": "665,504"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Stephen E. Gould Ph.D.", "age": 57, "title": "Chief Scientific Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 380517, "fmt": "380.52k", "longFmt": "380,517"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Herbert C. Cross", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Courtney J. Phillips J.D.", "age": 47, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Philippe C. Bishop M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}